Given the dense scientific debate on the role of EGFR and ALK mutations in NSCLC, aimed studies on BMs derived from this specific family of lung cancer should be carried out to explore their impact on diagnosis and treatment prognosis. This evidence concerns the gene EGFR and non-small cell lung carcinoma.